UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system. Issue 7 (3rd July 2018)

• Record Type: Journal Article
• Authors: Chen, Zhijuan; Ai, Lingbao; Mboge, Mam Y.; McKenna, Robert; Frost, Christopher J.; Heldermon, Coy D.; Frost, Susan C.
• Is Part Of: Cancer biology & therapy. Volume 19:Issue 7(2018)
• Page Start: 598
• Page End: 608
• Publication Date: 2018-07-03
• Subjects: breast cancer cells -- Breast Biology -- Cancer Biology -- Cancer Transcriptomes -- CAIX -- cell sorting -- microarray -- STR profiling -- triple negative model -- UFH-001; 616.99406
• DOI: 10.1080/15384047.2018.1449612
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Human cell lines are an important resource for research, and are often used as in vitro models of human diseases. In response to the mandate that all cells should be authenticated, we discovered that the MDA-MB-231 cells that were in use in our lab, did not validate based on the alleles of 9 different markers (STR Profile). We had been using this line as a model of triple negative breast cancer (TNBC) that has the ability to form tumors in immuno-compromised mice. Based on marker analysis, these cells most closely resembled the MCF10A line, which are a near diploid and normal mammary epithelial line. Yet, the original cells express carbonic anhydrase IX (CAIX) both constitutively and in response to hypoxia and are features that likely drive the aggressive nature of these cells. Thus, we sought to sub-purify CAIX-expressing cells using Fluorescence Activated Cell Sorting (FACS). These studies have revealed a new line of cells that we have name UFH-001, which have the TNBC phenotype, are positive for CAIX expression, both constitutively and in response to hypoxia, and behave aggressively in vivo . These cells may be useful for exploring mechanisms that underlie progression, migration, and metastasis of this phenotype. In addition, constitutive expression of CAIX allows its evaluation as a therapeutic target, both in vivo and in vitro .